M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Revelation Biosciences secures FDA acceptance for Gemini IND, Phase 1b CKD study set for 2025
Clinical-stage life sciences company Revelation Biosciences Inc (NASDAQ: REVB) announced on Monday that it has received FDA approval for its investigational new drug (IND) application for Gemini, paving the way for a Phase 1b clinical trial in early 2025. The study will evaluate Gemini as a...
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives
New Search